FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2062823432> ?p ?o ?g. }

• W2062823432 endingPage "297" @default.
• W2062823432 startingPage "290" @default.
• W2062823432 abstract "The life expectancy of Western populations has risen in the last few decades, resulting in a steep increase in the number of elderly cancer patients. Metastatic bone disease (MBD) is an important problem in such patients as it is associated with the development of skeletal-related events (SREs), such as fractures and spinal cord compression. These complications do not only deteriorate the quality of life of affected patients, but can also reduce expected survival. Due to the fact that elderly patients have an increased risk of SREs, maintaining bone health and implementing effective treatments for managing MBD is of vital importance. Bisphosphonates have been shown to be effective in reducing the risk of SREs considerably in patients with MBD. Moreover, they have been shown to reduce pain and improve the quality of life of affected patients. Bisphosphonates should be used with caution in elderly patients due to the fact that their use can bring about renal function deterioration. Several preventive measures need to be followed in order to minimise the risk of this complication. Denosumab is a monoclonal antibody inhibiting receptor activator of NF-kB ligand and has shown superiority over zoledronic acid in reducing the risk of SREs. In the three comparative trials between denosumab and zoledronic acid, survival and disease progression were similar between the two groups. Denosumab has been shown not to affect renal function and can therefore be safely used in the elderly. Osteonecrosis of the jaws is a devastating complication that may occur after treatment with either denosumab or zoledronic acid. The incidence rates between the two are comparable and percentage differences not statistically significant. In the three randomised trials, hypocalcaemia occurred more frequently in denosumab-treated patients than in those managed with zoledronic acid, with the corresponding percentages being 5.5–13% versus 3.4–6%. In order to minimise the risk of osteonecrosis of the jaws and hypocalcaemia, all precautionary measures and treatment guidelines should be followed closely. Several studies have investigated the cost-effectiveness of denosumab versus zoledronic acid when used for SRE prevention. These studies reported contradictory results due to the application of different analytical perspectives and model parameters." @default.
• W2062823432 created "2016-06-24" @default.
• W2062823432 creator A5038451893 @default.
• W2062823432 date "2013-05-01" @default.
• W2062823432 modified "2023-09-26" @default.
• W2062823432 title "Management of Metastatic Bone Disease in the Elderly with Bisphosphonates and Receptor Activator of NF-kB Ligand Inhibitors: Effectiveness and Safety" @default.
• W2062823432 cites W151221879 @default.
• W2062823432 cites W1530002712 @default.
• W2062823432 cites W1768011742 @default.
• W2062823432 cites W1906721103 @default.
• W2062823432 cites W1925515170 @default.
• W2062823432 cites W1954585625 @default.
• W2062823432 cites W1967615426 @default.
• W2062823432 cites W1969222077 @default.
• W2062823432 cites W1970446209 @default.
• W2062823432 cites W1987868778 @default.
• W2062823432 cites W1988303925 @default.
• W2062823432 cites W1989526399 @default.
• W2062823432 cites W2000096438 @default.
• W2062823432 cites W2010402011 @default.
• W2062823432 cites W2011926580 @default.
• W2062823432 cites W2013674541 @default.
• W2062823432 cites W2018855014 @default.
• W2062823432 cites W2027735110 @default.
• W2062823432 cites W2031211482 @default.
• W2062823432 cites W2032489540 @default.
• W2062823432 cites W2035237112 @default.
• W2062823432 cites W2036428904 @default.
• W2062823432 cites W2055870169 @default.
• W2062823432 cites W2061144117 @default.
• W2062823432 cites W2066000727 @default.
• W2062823432 cites W2068522538 @default.
• W2062823432 cites W2081417661 @default.
• W2062823432 cites W2083099771 @default.
• W2062823432 cites W2083956917 @default.
• W2062823432 cites W2086491566 @default.
• W2062823432 cites W2087929119 @default.
• W2062823432 cites W2088438928 @default.
• W2062823432 cites W2115871403 @default.
• W2062823432 cites W2134071321 @default.
• W2062823432 cites W2137302084 @default.
• W2062823432 cites W2139860898 @default.
• W2062823432 cites W2141521877 @default.
• W2062823432 cites W2142234592 @default.
• W2062823432 cites W2148845454 @default.
• W2062823432 cites W2149775776 @default.
• W2062823432 cites W2150126991 @default.
• W2062823432 cites W2152409486 @default.
• W2062823432 cites W2153630811 @default.
• W2062823432 cites W2157303837 @default.
• W2062823432 cites W2165011173 @default.
• W2062823432 cites W2166303017 @default.
• W2062823432 cites W2166769897 @default.
• W2062823432 cites W2325302070 @default.
• W2062823432 cites W24920798 @default.
• W2062823432 cites W4211048233 @default.
• W2062823432 cites W4230836190 @default.
• W2062823432 doi "https://doi.org/10.1016/j.clon.2013.01.008" @default.
• W2062823432 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23466465" @default.
• W2062823432 hasPublicationYear "2013" @default.
• W2062823432 type Work @default.
• W2062823432 sameAs 2062823432 @default.
• W2062823432 citedByCount "5" @default.
• W2062823432 countsByYear W20628234322013 @default.
• W2062823432 countsByYear W20628234322014 @default.
• W2062823432 countsByYear W20628234322015 @default.
• W2062823432 countsByYear W20628234322016 @default.
• W2062823432 countsByYear W20628234322022 @default.
• W2062823432 crossrefType "journal-article" @default.
• W2062823432 hasAuthorship W2062823432A5038451893 @default.
• W2062823432 hasConcept C118552586 @default.
• W2062823432 hasConcept C126322002 @default.
• W2062823432 hasConcept C143998085 @default.
• W2062823432 hasConcept C159110408 @default.
• W2062823432 hasConcept C2776169692 @default.
• W2062823432 hasConcept C2776286101 @default.
• W2062823432 hasConcept C2776326535 @default.
• W2062823432 hasConcept C2776541429 @default.
• W2062823432 hasConcept C2777251235 @default.
• W2062823432 hasConcept C2777556957 @default.
• W2062823432 hasConcept C2778231337 @default.
• W2062823432 hasConcept C2779134260 @default.
• W2062823432 hasConcept C2779951463 @default.
• W2062823432 hasConcept C2780775167 @default.
• W2062823432 hasConcept C71924100 @default.
• W2062823432 hasConceptScore W2062823432C118552586 @default.
• W2062823432 hasConceptScore W2062823432C126322002 @default.
• W2062823432 hasConceptScore W2062823432C143998085 @default.
• W2062823432 hasConceptScore W2062823432C159110408 @default.
• W2062823432 hasConceptScore W2062823432C2776169692 @default.
• W2062823432 hasConceptScore W2062823432C2776286101 @default.
• W2062823432 hasConceptScore W2062823432C2776326535 @default.
• W2062823432 hasConceptScore W2062823432C2776541429 @default.
• W2062823432 hasConceptScore W2062823432C2777251235 @default.
• W2062823432 hasConceptScore W2062823432C2777556957 @default.
• W2062823432 hasConceptScore W2062823432C2778231337 @default.
• W2062823432 hasConceptScore W2062823432C2779134260 @default.
• W2062823432 hasConceptScore W2062823432C2779951463 @default.

• next